Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2020

View Archived Issues

Noncoding mutations contribute to heart disease

Good vs. evil in the synovial joint

Topline data presented from global phase II trial of SEP-4199 in bipolar I depression

Discovery of novel HDAC6 selective inhibitors with potent preclinical activity

ImmunoGen presents next-generation FR-alpha-targeting ADC, IMGN-151

Dana-Farber Cancer Institute presents new MAPK9 inhibitors

Theravance Biopharma patents TGFR-1 inhibitors

Prelude Therapeutics discloses Mcl-1 inhibitors

RemeGen describes new angiogenesis inhibitors

ImmuneOnco Biopharmaceuticals divulges anti-PD-L1 and anti-VEGF compounds

Enrollment completed in pivotal DERBY and OAKS studies of pegcetacoplan

Novel innovative COVID-19 drug testing platform launched in the U.K.

Cabaletta Bio and Artisan Bio collaborate to develop next-generation CAAR T-cell therapies

Engineered interleukin-18 ignores tumors' defenses

Potent, orally available AXL inhibitor DW-17401 reduces xenograft tumor growth

Anti-CCR8 MAb BMS-986340 shows promise as cancer immunotherapeutic

Allogeneic anti-PTK7 CAR-T cells may allow safe access to the anticancer target

New phase I trial evaluates Curis' IRAK-4 kinase inhibitor CA-4948 in AML and MDS

Pivotal study of F-627 for chemotherapy-induced neutropenia meets primary and secondary endpoints

Anti-HER3 antibody shows efficacy in vivo against NRG1 fusion-bearing tumors

Inqovi approved in U.S. and Canada for MDS

InMed begins second phase I trial of INM-755 for epidermolysis bullosa

GSK and Medicago collaborate on adjuvanted COVID-19 candidate vaccine

STK-001 studied for Dravet syndrome in new phase I/II study

Corvus begins phase I study of CPI-006 in COVID-19

Hepion reports promising preclinical data with CRV-431 supporting potential for COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...